The synthetic intramembrane proteolysis receptor (SNIPR) is a groundbreaking tool designed to respond to soluble ligands with low baseline activity, allowing for high fold activation.
By enabling CAR T cells to specifically target solid tumors, the SNIPR platform addresses the significant challenge of off-target toxicity, enhancing the safety of such therapies.
This innovative receptor architecture opens new avenues for clinical applications, providing a means to create tailored cellular functions activated by both natural and synthetic ligands.
The ability to engineer synthetic signaling networks using SNIPR represents a major advancement in synthetic biology, expanding the potential for precise therapeutic interventions in various disease contexts.
Collection
[
|
...
]